ReCode Therapeutics to Participate in Upcoming November Investor Conferences

Menlo Park, Calif. and Dallas, Texas November 8, 2021ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will participate in two upcoming virtual investor conferences in November:

  • 2021 Stifel Healthcare Conference
    Format: Live Presentation
    Date: Monday, November 15, 2021
    Time: 4:40 p.m. – 5:10 p.m. ET
  • Piper Sandler 33rd Virtual Healthcare Conference
    Format: On-Demand Presentation
    Date: Monday, November 22, 2021
    Time: 10:00 a.m. ET
    Webcast: Link

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

CONTACTS

Media:
Will Zasadny
Canale Communications, Inc.
will.zasadny@canalecomm.com
(619) 961-8848

Investors:
Sarah McCabe
Stern Investor Relations
sarah.mccabe@sternir.com
IR@recodetx.com